A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma

Alberto S. Pappo, Laura C. Bowman, Wayne L. Furman, Bhaskar N. Rao, Larry E. Kun, Jesse J. Jenkins, William R. Crom, Xiaolong Luo, Sue C. Kaste, Loraine Avery, William H. Meyer, David N. Shapiro, William M. Crist

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: The outcome for children with advanced-stage rhabdomyosarcoma remains poor with contemporary treatment regimens. Evaluation of new drugs is important to improve clinical outcome. Because methotrexate has shown promising activity in the treatment of patients with recurrent rhabdomyosarcoma, we conducted a phase II trial in untreated children with advanced-stage disease to evaluate the efficacy and safety of this agent. Patients and Methods: Fifteen patients received 1 to 4 courses of high-dose methotrexate (HDMTX, 12 g/m2). Patients then received standard multiagent chemotherapy (vincristine, dactinomycin, cyclophosphamide, ifosfamide, mesna) with cytokine support and local radiotherapy. Patients who responded to HDMTX received four additional courses of this drug during continuation therapy. Results: Twelve patients were evaluable for response after 2 or more courses of HDMTX; 4 achieved a partial response (33.3%). After administration of standard chemotherapy and radiation, the estimated 2-year progression-free survival for all patients was 56% (SD 15%). The drug was well-tolerated and the most common side effects included mucositis, transient elevation of transaminases, and neutropenia. The four patients who received additional courses of HDMTX during continuation therapy had limited toxicity which included mucositis, anemia, and thrombocytopenia. Conclusions: About one- third of children with previously untreated advanced-stage rhabdomyosarcoma responded to HDMTX. Its different mechanism of action and non-overlapping toxicity with other agents make HDMTX an attractive candidate for incorporation into front-line treatment regimens for rhabdomyosarcoma.

Original languageEnglish (US)
Pages (from-to)438-442
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume19
Issue number5
DOIs
StatePublished - Jan 1 1997

Fingerprint

Rhabdomyosarcoma
Methotrexate
Mucositis
Mesna
Therapeutics
Drug Therapy
Ifosfamide
Drug Evaluation
Dactinomycin
Vincristine
Transaminases
Neutropenia
Thrombocytopenia
Pharmaceutical Preparations
Cyclophosphamide
Disease-Free Survival
Anemia
Radiotherapy
Radiation
Cytokines

Keywords

  • Methotrexate
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. / Pappo, Alberto S.; Bowman, Laura C.; Furman, Wayne L.; Rao, Bhaskar N.; Kun, Larry E.; Jenkins, Jesse J.; Crom, William R.; Luo, Xiaolong; Kaste, Sue C.; Avery, Loraine; Meyer, William H.; Shapiro, David N.; Crist, William M.

In: Journal of Pediatric Hematology/Oncology, Vol. 19, No. 5, 01.01.1997, p. 438-442.

Research output: Contribution to journalArticle

Pappo, AS, Bowman, LC, Furman, WL, Rao, BN, Kun, LE, Jenkins, JJ, Crom, WR, Luo, X, Kaste, SC, Avery, L, Meyer, WH, Shapiro, DN & Crist, WM 1997, 'A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma', Journal of Pediatric Hematology/Oncology, vol. 19, no. 5, pp. 438-442. https://doi.org/10.1097/00043426-199709000-00006
Pappo, Alberto S. ; Bowman, Laura C. ; Furman, Wayne L. ; Rao, Bhaskar N. ; Kun, Larry E. ; Jenkins, Jesse J. ; Crom, William R. ; Luo, Xiaolong ; Kaste, Sue C. ; Avery, Loraine ; Meyer, William H. ; Shapiro, David N. ; Crist, William M. / A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. In: Journal of Pediatric Hematology/Oncology. 1997 ; Vol. 19, No. 5. pp. 438-442.
@article{a2600dbfb16d4b81966345e23d5f5857,
title = "A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma",
abstract = "Purpose: The outcome for children with advanced-stage rhabdomyosarcoma remains poor with contemporary treatment regimens. Evaluation of new drugs is important to improve clinical outcome. Because methotrexate has shown promising activity in the treatment of patients with recurrent rhabdomyosarcoma, we conducted a phase II trial in untreated children with advanced-stage disease to evaluate the efficacy and safety of this agent. Patients and Methods: Fifteen patients received 1 to 4 courses of high-dose methotrexate (HDMTX, 12 g/m2). Patients then received standard multiagent chemotherapy (vincristine, dactinomycin, cyclophosphamide, ifosfamide, mesna) with cytokine support and local radiotherapy. Patients who responded to HDMTX received four additional courses of this drug during continuation therapy. Results: Twelve patients were evaluable for response after 2 or more courses of HDMTX; 4 achieved a partial response (33.3{\%}). After administration of standard chemotherapy and radiation, the estimated 2-year progression-free survival for all patients was 56{\%} (SD 15{\%}). The drug was well-tolerated and the most common side effects included mucositis, transient elevation of transaminases, and neutropenia. The four patients who received additional courses of HDMTX during continuation therapy had limited toxicity which included mucositis, anemia, and thrombocytopenia. Conclusions: About one- third of children with previously untreated advanced-stage rhabdomyosarcoma responded to HDMTX. Its different mechanism of action and non-overlapping toxicity with other agents make HDMTX an attractive candidate for incorporation into front-line treatment regimens for rhabdomyosarcoma.",
keywords = "Methotrexate, Rhabdomyosarcoma",
author = "Pappo, {Alberto S.} and Bowman, {Laura C.} and Furman, {Wayne L.} and Rao, {Bhaskar N.} and Kun, {Larry E.} and Jenkins, {Jesse J.} and Crom, {William R.} and Xiaolong Luo and Kaste, {Sue C.} and Loraine Avery and Meyer, {William H.} and Shapiro, {David N.} and Crist, {William M.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1097/00043426-199709000-00006",
language = "English (US)",
volume = "19",
pages = "438--442",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma

AU - Pappo, Alberto S.

AU - Bowman, Laura C.

AU - Furman, Wayne L.

AU - Rao, Bhaskar N.

AU - Kun, Larry E.

AU - Jenkins, Jesse J.

AU - Crom, William R.

AU - Luo, Xiaolong

AU - Kaste, Sue C.

AU - Avery, Loraine

AU - Meyer, William H.

AU - Shapiro, David N.

AU - Crist, William M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Purpose: The outcome for children with advanced-stage rhabdomyosarcoma remains poor with contemporary treatment regimens. Evaluation of new drugs is important to improve clinical outcome. Because methotrexate has shown promising activity in the treatment of patients with recurrent rhabdomyosarcoma, we conducted a phase II trial in untreated children with advanced-stage disease to evaluate the efficacy and safety of this agent. Patients and Methods: Fifteen patients received 1 to 4 courses of high-dose methotrexate (HDMTX, 12 g/m2). Patients then received standard multiagent chemotherapy (vincristine, dactinomycin, cyclophosphamide, ifosfamide, mesna) with cytokine support and local radiotherapy. Patients who responded to HDMTX received four additional courses of this drug during continuation therapy. Results: Twelve patients were evaluable for response after 2 or more courses of HDMTX; 4 achieved a partial response (33.3%). After administration of standard chemotherapy and radiation, the estimated 2-year progression-free survival for all patients was 56% (SD 15%). The drug was well-tolerated and the most common side effects included mucositis, transient elevation of transaminases, and neutropenia. The four patients who received additional courses of HDMTX during continuation therapy had limited toxicity which included mucositis, anemia, and thrombocytopenia. Conclusions: About one- third of children with previously untreated advanced-stage rhabdomyosarcoma responded to HDMTX. Its different mechanism of action and non-overlapping toxicity with other agents make HDMTX an attractive candidate for incorporation into front-line treatment regimens for rhabdomyosarcoma.

AB - Purpose: The outcome for children with advanced-stage rhabdomyosarcoma remains poor with contemporary treatment regimens. Evaluation of new drugs is important to improve clinical outcome. Because methotrexate has shown promising activity in the treatment of patients with recurrent rhabdomyosarcoma, we conducted a phase II trial in untreated children with advanced-stage disease to evaluate the efficacy and safety of this agent. Patients and Methods: Fifteen patients received 1 to 4 courses of high-dose methotrexate (HDMTX, 12 g/m2). Patients then received standard multiagent chemotherapy (vincristine, dactinomycin, cyclophosphamide, ifosfamide, mesna) with cytokine support and local radiotherapy. Patients who responded to HDMTX received four additional courses of this drug during continuation therapy. Results: Twelve patients were evaluable for response after 2 or more courses of HDMTX; 4 achieved a partial response (33.3%). After administration of standard chemotherapy and radiation, the estimated 2-year progression-free survival for all patients was 56% (SD 15%). The drug was well-tolerated and the most common side effects included mucositis, transient elevation of transaminases, and neutropenia. The four patients who received additional courses of HDMTX during continuation therapy had limited toxicity which included mucositis, anemia, and thrombocytopenia. Conclusions: About one- third of children with previously untreated advanced-stage rhabdomyosarcoma responded to HDMTX. Its different mechanism of action and non-overlapping toxicity with other agents make HDMTX an attractive candidate for incorporation into front-line treatment regimens for rhabdomyosarcoma.

KW - Methotrexate

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0031423784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031423784&partnerID=8YFLogxK

U2 - 10.1097/00043426-199709000-00006

DO - 10.1097/00043426-199709000-00006

M3 - Article

C2 - 9329466

AN - SCOPUS:0031423784

VL - 19

SP - 438

EP - 442

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 5

ER -